The effect of ziltivekimab on the neutrophil-lymphocyte ratio: analysis from RESCUE

29 August 2022 (09:15 - 10:00)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Nicholas Adamstein

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

7 More presentations in this session

Presentation thumbnail

High-sensitivity troponin (hs-Tn) for cardiovascular risk prognostication: a systematic review and meta-analysis

Doctor M. Sagris (Athens, GR)

Abstract Slides

Presentation thumbnail

Long-term prognostic value of trimethylamine N-oxide in community-based adults and patients with coronary heart disease

Doctor E. Bjornestad (Stavanger, NO)

Abstract Slides

Presentation thumbnail

Ultra-sensitive troponin-I and incident coronary heart disease, stroke, heart failure, cardiac arrhythmias, arterial aneurysms and venous thromboembolism hospitalizations

Professor J. Empana (Paris, FR)

Abstract Slides

Presentation thumbnail

High-sensitive Troponin T is not associated with the progression of asymptomatic mild to moderate aortic stenosis: a post hoc substudy of the SEAS trial

Doctor E. Hadziselimovic (Copenhagen, DK)

Abstract Slides

Presentation thumbnail

Elevated high-sensitivity C-reactive protein and the risk for cardiovascular events in chronic cardiac disease

Professor J. Bergler-Klein (Vienna, AT)

Abstract Slides

Access the full session

Session thumbnail

Cardiovascular risk assessment - Biomarkers 2

The Event

Event poster

ESC Congress 2022

29 August 2022 09:15 CET

You may be interested in

Webinar

Biomarkers of clinical utility in cardiovascular disease

Congress Session

Challenges and innovations in cardiovascular risk stratification with cardiac biomarkers

Webinar

Personalised secondary prevention post-ACS: the role of biomarkers

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources